Iris Isufi

892 total citations
61 papers, 535 citations indexed

About

Iris Isufi is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Iris Isufi has authored 61 papers receiving a total of 535 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Pathology and Forensic Medicine, 32 papers in Oncology and 28 papers in Genetics. Recurrent topics in Iris Isufi's work include Lymphoma Diagnosis and Treatment (31 papers), Chronic Lymphocytic Leukemia Research (25 papers) and CAR-T cell therapy research (20 papers). Iris Isufi is often cited by papers focused on Lymphoma Diagnosis and Treatment (31 papers), Chronic Lymphocytic Leukemia Research (25 papers) and CAR-T cell therapy research (20 papers). Iris Isufi collaborates with scholars based in United States, United Kingdom and Canada. Iris Isufi's co-authors include Muhammad Wasif Saif, Kristin Kaley, Stuart Seropian, Scott F. Huntington, Frederick Lansigan, Clément E. Tagoe, Francine M. Foss, Lohith Gowda, Davendra Sohal and Li Zhou and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Lara D. Veeken.

In The Last Decade

Iris Isufi

53 papers receiving 528 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Iris Isufi United States	12	283	159	150	127	121	61	535
Filiz Şen United States	16	213 0.8×	278 1.7×	124 0.8×	117 0.9×	163 1.3×	42	623
Christine McIntyre Switzerland	14	303 1.1×	202 1.3×	146 1.0×	39 0.3×	201 1.7×	31	634
Liliana Morales Argentina	2	144 0.5×	69 0.4×	134 0.9×	236 1.9×	141 1.2×	2	625
Guilherme Fleury Perini Brazil	12	163 0.6×	156 1.0×	67 0.4×	75 0.6×	124 1.0×	47	462
Radovan Vrḫovac Croatia	15	253 0.9×	227 1.4×	157 1.0×	243 1.9×	330 2.7×	65	810
Mike Leach United Kingdom	12	168 0.6×	250 1.6×	163 1.1×	100 0.8×	190 1.6×	37	525
Bozena Möller Sweden	9	203 0.7×	74 0.5×	471 3.1×	72 0.6×	60 0.5×	12	962
Idanna Innocenti Italy	14	131 0.5×	227 1.4×	181 1.2×	152 1.2×	336 2.8×	75	638
Sumie Hiramatsu Japan	13	143 0.5×	59 0.4×	173 1.2×	47 0.4×	51 0.4×	37	477
Asma Beldi‐Ferchiou France	13	348 1.2×	145 0.9×	420 2.8×	66 0.5×	54 0.4×	21	813

Countries citing papers authored by Iris Isufi

Since Specialization

Citations

This map shows the geographic impact of Iris Isufi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Iris Isufi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Iris Isufi more than expected).

Fields of papers citing papers by Iris Isufi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Iris Isufi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Iris Isufi. The network helps show where Iris Isufi may publish in the future.

Co-authorship network of co-authors of Iris Isufi

This figure shows the co-authorship network connecting the top 25 collaborators of Iris Isufi. A scholar is included among the top collaborators of Iris Isufi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Iris Isufi. Iris Isufi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Isufi, Iris, Jennifer L. Crombie, Matthew J. Frigault, et al.. (2025). Effectiveness and Safety Outcomes of Standard of Care (SOC) Lisocabtagene Maraleucel (liso-cel) in Patients (Pts) with Relapsed or Refractory (R/R) Transformed Large B-Cell Lymphoma (tLBCL): Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry. Transplantation and Cellular Therapy. 31(2). S215–S215.

Mei, Matthew, Joycelynne Palmer, Hun Ju Lee, et al.. (2025). Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high‐risk relapsed/refractory Hodgkin lymphoma. HemaSphere. 9(5). e70126–e70126.

Kamdar, Manali, Sairah Ahmed, Jeremy S. Abramson, et al.. (2025). CT-305: Optimizing Post-Chimeric Antigen Receptor (CAR) T-Cell Monitoring: Evidence Across Lisocabtagene Maraleucel (liso-cel) Pivotal Clinical Trials and Real-World Experience. Clinical Lymphoma Myeloma & Leukemia. 25. S1010–S1011.

Hunter, Bradley D., Matthew A. Lunning, Sairah Ahmed, et al.. (2025). CRS or ICANS Are Rare Beyond 2 Weeks After Lisocabtagene Maraleucel Infusion: Data From Clinical Trials and the Real-World Setting. Transplantation and Cellular Therapy. 32(2). 171.e1–171.e12. 1 indexed citations

Cahill, Kirk E., James Godfrey, Chadi Nabhan, et al.. (2025). A multicenter phase 1/2 trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated DLBCL. Blood Advances. 9(21). 5665–5675.

Gehrie, Eric A., Pampee P. Young, Sridhar V. Basavaraju, et al.. (2024). Addressing platelet insecurity – A national call to action. Transfusion. 64(10). 2001–2013. 6 indexed citations

Foss, Francine, Sonal Agarwal, Iris Isufi, et al.. (2024). Real World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 25(2). e96–e102.

Ghobadi, Armin, Caron A. Jacobson, Joseph P. McGuirk, et al.. (2024). Phase 2 open label, multicenter study evaluating CRG-022, a CD22-directed autologous CAR T-cell therapy, in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after CD19-directed CAR T-cell therapy.. Journal of Clinical Oncology. 42(16_suppl). TPS7085–TPS7085. 1 indexed citations

Tun, Han W., Allison Rosenthal, Matthew A. Lunning, et al.. (2023). Takeaim Lymphoma: An Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Combination with Ibrutinib in Patients with Relapsed or Refractory Hematologic Malignancies. Blood. 142(Supplement 1). 4497–4497. 3 indexed citations

10.

Cheah, Chan Y., Nancy L. Bartlett, Sarit Assouline, et al.. (2023). IBCL-489 Mosunetuzumab Retreatment Is Effective and Well-Tolerated in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 23. S455–S455.

11.

Di, Mengyang, Iris Isufi, Lohith Gowda, et al.. (2022). Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma. Blood Advances. 7(5). 801–810. 38 indexed citations

12.

Holowka, Thomas, Maricar Malinis, Geliang Gan, et al.. (2021). Incidence and associated risk factors for invasive fungal infections and other serious infections in patients on ibrutinib. Journal of Infection and Chemotherapy. 27(12). 1700–1705. 9 indexed citations

13.

Barbarotta, Lisa, Osama Abdelghany, Francine Foss, et al.. (2021). Mitigating the risk of COVID-19 exposure by transitioning from clinic-based to home-based immune globulin infusion. American Journal of Health-System Pharmacy. 78(12). 1112–1117. 10 indexed citations

14.

Younes, Anas, Grzegorz S. Nowakowski, Allison Rosenthal, et al.. (2019). Phase 1 Study of CA-4948, a Novel Inhibitor of Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) in Patients with R/R Non-Hodgkin Lymphoma (NHL). Clinical Lymphoma Myeloma & Leukemia. 19. S256–S257. 3 indexed citations

15.

Budde, Lihua E., Laurie H. Sehn, Sarit Assouline, et al.. (2018). Mosunetuzumab, a Full-Length Bispecific CD20/CD3 Antibody, Displays Clinical Activity in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL): Interim Safety and Efficacy Results from a Phase 1 Study. Blood. 132(Supplement 1). 399–399. 44 indexed citations

16.

Subtil, Antonio, et al.. (2017). Transplantation in the Treatment of Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8-Positive T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 18(1). e85–e93. 9 indexed citations

17.

Foss, Francine, et al.. (2016). Infusion reactions are common after high-dose carmustine in BEAM chemotherapy and are not reduced by lengthening the time of administration. Supportive Care in Cancer. 25(1). 205–208. 1 indexed citations

18.

Seropian, Stuart, et al.. (2015). The use of basiliximab–infliximab combination for the treatment of severe gastrointestinal acute GvHD. Bone Marrow Transplantation. 51(2). 273–276. 19 indexed citations

19.

Lansigan, Frederick, Iris Isufi, & Clément E. Tagoe. (2010). Microangiopathic haemolytic anaemia resembling thrombotic thrombocytopenic purpura in systemic lupus erythematosus: the role of ADAMTS13. Lara D. Veeken. 50(5). 824–829. 40 indexed citations

20.

Isufi, Iris, Mahesh Seetharam, Li Zhou, et al.. (2007). Transforming Growth Factor- β Signaling in Normal and Malignant Hematopoiesis. Journal of Interferon & Cytokine Research. 27(7). 543–552. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact